ReviewDrugs2011
MMX® Mesalazine: a review of its use in the management of mild to moderate ulcerative colitis.
Review in Drugs, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- A review of the biological and pharmacological activities of mesalazine or 5-aminosalicylic acid (5-ASA): an anti-ulcer and anti-oxidant drug.Inflammopharmacology · 2021Pooled it
- From guidelines to evidence-based practice - A German perspective on mesalazine as first-line therapy for mild-to-moderate ulcerative colitis.Zeitschrift fur Gastroenterologie · 2025Review
- ROS/Enzyme Dual-Responsive Drug Delivery System for Targeted Colorectal Cancer Therapy: Synergistic Chemotherapy, Anti-Inflammatory, and Gut Microbiota Modulation.Pharmaceutics · 2025Article
- Systems-level biomarkers identification and drug repositioning in colorectal cancer.World journal of gastrointestinal oncology · 2021Review
- Copper mediated C-H amination with oximes: en route to primary anilines.Chemical science · 2018Article
- Recent advances in understanding ulcerative colitis.Internal and emergency medicine · 2012Review
- Mesalamine in the treatment and maintenance of remission of ulcerative colitis.Expert review of clinical pharmacology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Multi MatriX system (MMX®) formulation of mesalazine (Lialda®; Mesavancol®; Mezavant®) [henceforth referred to as MMX mesalazine] is an oral, high-dose, once-daily, gastro-resistant, prolonged-release formulation indicated for use in patients with mild to moderate ulcerative colitis. Mesalazine has numerous anti-inflammatory effects on the mucosa of the colon, parts of which are frequently inflamed in ulcerative colitis. MMX mesalazine is believed to act topically. Therapy with MMX mesalazine 2.4 or 4.8 g once daily for 8 weeks was superior to placebo in inducing clinical and endoscopic remission in patients with mild to moderate ulcerative colitis. In 12-month maintenance trials, MMX mesalazine 2.4 g/day maintained remission in about two-thirds of patients and was as effective as Asacol® 2.4 g/day (another oral formulation of mesalazine) as maintenance therapy. In general, MMX mesalazine was well tolerated in both short- and long-term clinical trials; its tolerability profile did not differ clinically to that of placebo or Asacol®. The majority of adverse events reported in clinical trials were gastrointestinal in nature. Therefore, MMX mesalazine appears to be a valuable option in the management of patients with mild to moderate ulcerative colitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.